Lexaria to Present and Meet with Investors One-on-One at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021

March 11, 2021 7:10 AM

Lexaria recently expanded its hypertension R&D program evaluating effectiveness of DehydraTECH-processed CBD to three human clinical studies and two animal studies KELOWNA, BC / ACCESSWIRE / March 11, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that CEO Chris Bunka is presenting and will be...

Read more

American CryoStem Announces Patient Biomaterial Processing for its Post-Concussion Syndrome (PCS) Phase I Clinical Trial

March 11, 2021 3:00 AM

EATONTOWN, NJ / ACCESSWIRE / March 11, 2021 / American CryoStem Corporation (OTC: CRYO) a clinical stage biotechnology company, global licensor and a pioneer in autologous cellular processing and therapies announced today that it has begun processing patient's adipose tissue and culturing mesenchymal stem cells (ATCell™), for use in its FDA approved IND Phase I Clinical Trial. The Company's autologous mesenchymal stem cell...

Read more

Molecular Partners Nominates Agnete Fredriksen for Election to Its Board of Directors

March 11, 2021 1:00 AM

Acknowledged innovation leader with deep scientific and business expertise in immunotherapy, oncology and infectious diseases ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 11, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the nomination of Agnete Fredriksen, Ph.D., to the Company's Board of...

Read more

Molecular Partners to Present Data from Localized Immune Agonist (MP0317), T-cell Engager, and Peptide-MHC Immunotherapy Programs at AACR Annual Meeting

March 10, 2021 5:00 PM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 10, 2021. Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the upcoming presentation of four posters with data supporting three of the company's immunotherapy programs at the American Academy for Cancer Research (AACR) Virtual Annual Meeting running April 10-15,...

Read more

AdOM Advanced Optical Technologies Ltd. Announces the Launch of the Tear Film Imager (TFI) Device in the U.S.

March 10, 2021 10:45 AM

LOD, ISRAEL / ACCESSWIRE / March 10, 2021 / AdOM Advanced Optical technologies Ltd., a clinical and commercial stage ophthalmic medical device company, announces the launch of the Tear Film Imager (TFI) device in the U.S. The TFI is a non-invasive imaging device which is designed to simultaneously measure the muco-aqueous and lipid sublayers of the eye, at a dept resolution of nanometer level. It's use involves a brief 40 second exam per...

Read more

Biotech Medics, Inc. Provides A Company Update on The Company’s New Business Plan For 2021

March 10, 2021 9:00 AM

WOODLAND HILLS, CA / ACCESSWIRE / March 10, 2021 / BioTech Medics, Inc. (OTC PINK:BMCS) is pleased to announce that the firm has been making significant steps to transform BMCS into an new and more productive business model. Management is moving into the crypto space, an emerging growth marketplace. According to Anthony K. Miller, CEO, "as I mentioned before, we have been working diligently for over a year to make this change and we are...

Read more

MJ Biotech, Inc. Submits Final Designs for CBD Extraction Facility, and A Second Foundation for Further Expansion

March 10, 2021 7:55 AM

CHEYENNE, WY / ACCESSWIRE / March 10, 2021 / MJ Biotech, Inc. (OTC PINK:MJTV), partner Genesis Botanical Research (GBR), is pleased to report they have broken ground on a second foundation which will be used to store hemp biomass. Plans for the structure arrived at GBR corporate offices, several contractors are currently placing. bids for the erection of the structure. Upon completion of this process plans will be submitted for official town...

Read more

GeneCentric Therapeutics Announces New US Patent Granted for Molecular Characterization of Non-Squamous Non-Small Cell Lung Cancer

March 9, 2021 8:00 AM

Patent Provides Framework for Further Development of Novel Lung Cancer Molecular Diagnostic Tests DURHAM, NC / ACCESSWIRE / March 9, 2021 / GeneCentric Therapeutics, a company making precision medicine more precise, announced today the granting of Patent No. 10,934,595 by the United States Patent and Trademark Office (USPTO), protecting another one of its novel RNA-based lung cancer gene signatures. This new patent provides further...

Read more

Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone

March 9, 2021 7:30 AM

TORONTO, ON / ACCESSWIRE / March 9, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has completed enrollment of the first cohort of a Phase 2b clinical study evaluating the company's drug candidate EB01 as a monotherapy for chronic Allergic Contact Dermatitis (ACD), a potentially debilitating condition and occupational...

Read more

Vitro Biopharma Year ended October 31st, 2020 Financial Results of Operations and Shareholder Letter

March 9, 2021 6:00 AM

GOLDEN, CO / ACCESSWIRE / March 9, 2021 / Vitro Biopharma Inc. (formerly Vitro Diagnostics Inc.) (dba Vitro Biopharma), announced its year ended October 31st, 2020, financial results of operations. Vitro Biopharma recorded year ended October 31st, 2020 revenues of $ 648,708 vs $882,037 a decrease of 26% over the prior year directly attributed to the COVID-19 pandemic. Revenues in the fourth quarter of 2020 of $161,888 were up 23% over the...

Read more

Molecular Partners and Novartis Report Positive Initial Results from Phase 1 Study of its COVID-19 Antiviral Therapy, Ensovibep, in Healthy Volunteers

March 9, 2021 1:00 AM

Initial findings show ensovibep to be safe and well tolerated with no significant adverse events Predictable exposure seen post administration, confirming the expected half-life of 2‑3 weeks Global phase 2/3 registrational study planned to initiate in Q2 2021 ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 9, 2021 / Molecular Partners AG (SWX: MOLN), a clinical-stage biotech company that is developing a new class of...

Read more

OMNICANNA/Thermic Sciences Acquires 100% of Another European Groundbreaking Technology; Litcoat Electroluminescent Paint, Known as Multi-Colored Electrical Lighting Paint for Cars, Boats, Motorcycles, Billboards, Buildings, Houses, Bicycles, and So Much More

March 8, 2021 9:28 AM

NASHVILLE, TN / ACCESSWIRE / March 8, 2021 / Thermic Sciences International, former known as Omnicanna Health Solutions, Inc. aka ENDOCAN CORP. (WKN: A1W61J, ISIN: US29271J1097, OTC PINK:ENDO), acquires another groundbreaking technology to adds to its growing list of acquisitions building strong towards its corporate conglomerate being coined as the latest North American powerhouse SPAC, 100% rights, assets and operations acquisition of Litcoat...

Read more

Correction To Tetra Bio-Pharma News Release Dated February 25th

March 8, 2021 9:00 AM

OTTAWA, ON / ACCESSWIRE / March 8, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP)(OTCQB: TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development wishes to make the following correction to its news release dated February 25th, 2021. In the statement attributed to DanCann Pharma's CCO John Morell Frellsen, the estimate of peak sales by 2026 is cited at $55M DKK. In fact,...

Read more

Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial

March 8, 2021 8:30 AM

IRVINE, CA / ACCESSWIRE / March 8, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) seeking approval to begin a U.S. pivotal trial for the VenoValve®. The VenoValve is an implantable valve designed to restore proper directional...

Read more

Apollo Endosurgery announces AMA assignment of Category I CPT Codes for use in Intragastric Balloon Procedures

March 8, 2021 8:30 AM

AUSTIN, TX / ACCESSWIRE / March 8, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced the assignment of Category I Current Procedural Terminology (CPT®) codes with short form descriptor esophagogastroduodenoscopy with deployment of gastric bariatric device (e.g., balloon) under endoscopic guidance. The codes and...

Read more

Community and Business Joining Together to Safely Reopen America

March 8, 2021 8:00 AM

WASHINGTON, DC / ACCESSWIRE / March 8, 2021 / Business leaders and community organizations have joined forces to support R.E.S.T., "Reopening Effectively and Safely Together", a multi-state mission and initiative created and designed to address the tough challenges ahead as we look forward to the post-COVID-19 world. Assembly of Petworth Healthcare Coalition, MAD Konnect LLC, and Oxi-Thyme North America, Inc., have cooperatively...

Read more

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference

March 3, 2021 8:05 AM

FRAMINGHAM, MA / ACCESSWIRE / March 3, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at the virtual H.C. Wainwright Global Life Sciences...

Read more

Apollo Endosurgery to Present at HC Wainwright Global Life Sciences Conference

March 3, 2021 8:00 AM

AUSTIN, TX / ACCESSWIRE / March 3, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that it will participate in the H.C. Wainwright Global Life Sciences Conference taking place virtually March 9-10, 2021. Management will provide a pre-recorded presentation which will be available to registered investors on demand...

Read more

Tetra Bio-Pharma to Present at the H.C. Wainwright Global Life Sciences Virtual Conference

March 3, 2021 7:00 AM

OTTAWA, ON / ACCESSWIRE / March 3, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development announces that CEO Dr. Guy Chamberland will present a company overview and hold virtual investor meetings at the H.C. Wainwright Global Life Sciences Virtual Conference being held March 9-10, 2021. The Tetra Bio-Pharma webcast...

Read more

Edesa Biotech Announces Closing of $10 Million Bought Deal Offering of Common Shares

March 2, 2021 4:10 PM

TORONTO, ON / ACCESSWIRE / March 2, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the closing of its previously announced underwritten public offering of 1,562,500 common shares of Edesa, at a price to the public of $6.40 per share, less underwriting discounts and commissions. The gross proceeds were $10.0 million, before deducting...

Read more